July 2013 Newsletter

July 15, 2013:

US Refractive Surgery Volume Slips 13 Percent in Q1-2013

The 13 percent decline in procedures during the seasonally strongest first quarter casts a shadow over the year.

July 15, 2013:

FDA Approves Key Ophthalmic Products in First Half of Year

The AMO TECNIS Toric and Bausch + Lomb Trulign IOLs are among several noteworthy ophthalmic products to receive FDA regulatory approval in the first half of 2013.

July 15, 2013:

US IOL Procedures Climb 3.1 Percent in Q1-2013

Survey respondents reported a modest growth in premium IOL procedure share when compared with the same quarter last year.

July 15, 2013:

Med-Logics Catapulse Nears Market Launch, Offers Phaco Without Ultrasound

The Catapulse uses pulsed vacuum to break up the cataract lens instead of ultrasonic energy, thereby avoiding the drawbacks of ultrasonic energy propagation.

July 15, 2013:

Retina Implant AG Gains CE Mark for Alpha IMS Retinal Prosthetic

The Alpha IMS is a subretinal implant placed beneath the fovea at the level of the photoreceptors. This contrasts with the epiretinal ARGUS II’s microchip, which is positioned atop the retina.

July 15, 2013:

Pay-for-Delay Deals That Slow the Development of Generics Can Be Challenged by FTC, Court Rules

The Federal Trade Commission (FTC) can file an antitrust lawsuit against pharmaceutical companies that pay generic drug makers to keep their drugs off the market, the Supreme Court has ruled.

July 15, 2013:

Supreme Court Rules Against Patenting of Human Genes

However, the court said that synthetically created DNA (known as cDNA) is patentable since it is not naturally occurring.

July 15, 2013:

FDA Proposes Revised Bioequivalence Guidance for Generic Challengers to Restasis

The proposed guidance would allow companies to apply for marketing approval of generic versions of Restasis based on laboratory tests, not on human clinical trials.

July 15, 2013:

July 2013 News Briefs

Social media